Capital International Investors Has $6.94 Million Stake in Zai Lab Limited (NASDAQ:ZLAB)

Capital International Investors lifted its holdings in shares of Zai Lab Limited (NASDAQ:ZLAB) by 82.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 264,986 shares of the company’s stock after purchasing an additional 120,000 shares during the quarter. Capital International Investors’ holdings in Zai Lab were worth $6,940,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. Pictet Asset Management Holding SA acquired a new stake in Zai Lab during the 4th quarter worth approximately $31,000. Barclays PLC raised its holdings in shares of Zai Lab by 337.6% during the fourth quarter. Barclays PLC now owns 3,702 shares of the company’s stock worth $97,000 after acquiring an additional 2,856 shares during the period. US Bancorp DE lifted its position in Zai Lab by 1,671.9% in the 4th quarter. US Bancorp DE now owns 5,865 shares of the company’s stock valued at $154,000 after acquiring an additional 5,534 shares in the last quarter. Townsquare Capital LLC acquired a new position in Zai Lab in the 4th quarter worth $243,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Zai Lab by 15.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,061 shares of the company’s stock worth $290,000 after purchasing an additional 1,502 shares during the period. Institutional investors own 41.65% of the company’s stock.

Wall Street Analyst Weigh In

ZLAB has been the subject of several recent research reports. Scotiabank began coverage on Zai Lab in a research report on Friday, March 7th. They set a “sector outperform” rating and a $55.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zai Lab in a research note on Thursday, March 27th. Bank of America reissued a “neutral” rating and issued a $36.10 price objective (up previously from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd. Finally, JPMorgan Chase & Co. increased their target price on shares of Zai Lab from $44.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, March 13th.

Zai Lab Stock Down 0.3 %

Shares of Zai Lab stock opened at $28.84 on Monday. The stock has a market cap of $3.16 billion, a P/E ratio of -10.41 and a beta of 1.09. Zai Lab Limited has a 12-month low of $14.48 and a 12-month high of $39.77. The business’s 50 day moving average is $32.97 and its 200-day moving average is $29.30.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.19). The firm had revenue of $109.07 million for the quarter, compared to the consensus estimate of $110.15 million. Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. On average, sell-side analysts expect that Zai Lab Limited will post -2.58 EPS for the current year.

Insiders Place Their Bets

In related news, insider Rafael Amado sold 3,000 shares of Zai Lab stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $38.41, for a total transaction of $115,230.00. Following the completion of the sale, the insider now owns 30,834 shares of the company’s stock, valued at approximately $1,184,333.94. The trade was a 8.87 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Ying Du sold 50,000 shares of the stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $34.47, for a total transaction of $1,723,500.00. Following the completion of the transaction, the chief executive officer now directly owns 494,117 shares in the company, valued at approximately $17,032,212.99. This represents a 9.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 138,744 shares of company stock valued at $4,685,294 over the last 90 days. 13.88% of the stock is currently owned by insiders.

Zai Lab Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.